\
Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Board of Directors

Gary S. Jacob, Ph.D.

Committees: Executive Compensation Committee, Corporate Governance and Nominating Committee

Gary Jacob has been a Director since February 2009. He is Chief Executive Officer of Immuron Limited, an Australian public biotechnology company, where he has served since November 2018 and has been Chairman of Hepion Pharmaceuticals, Inc. since 2013. From 2008 to 2017, Dr. Jacob served as President and Chief Executive Officer of Synergy Pharmaceuticals, Inc. and as Chairman from 2013 to 2018. In December of 2018, Synergy Pharmaceuticals, Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from 2003 to 2013 and as Director from 2004 until its merger with Synergy Pharmaceuticals, Inc. in 2013. The Board believes Dr. Jacob’s broad management expertise in the pharmaceutical and biotechnology industry provides relevant experience in a number of strategic and operational areas that qualifies him to serve as a director of our company.